美国2-5岁儿童接种单价COVID-19 mRNA疫苗后热性惊厥风险
该研究在三个商业保险数据库中采用自身对照病例系列分析,评估2-5岁儿童接种单价COVID-19 mRNA疫苗后0-1天内热性惊厥风险。主要分析显示,接种mRNA-1273后0-1天热性惊厥发生率显著升高(IRR 2.52,95%CI 1.35-4.69),而BNT162b2后IRR升高但无统计学意义(IRR 1.41,95%CI 0.48-4.11)。
要点
- 2-5岁儿童接种mRNA-1273后0-1天热性惊厥风险显著升高,IRR为2.52。
- BNT162b2接种后热性惊厥风险升高但无统计学意义,IRR为1.41。
- mRNA-1273每10万剂风险差为3.22,绝对风险增加较小。
核心结论
- 在2-5岁儿童中,接种mRNA-1273后0-1天内热性惊厥发生率比值小幅升高。
研究设计与样本
- 自身对照病例系列分析,基于三个商业保险数据库,比较接种后风险 interval(0-1天)与对照 interval(8-63天)。
- 暴露为接种单价COVID-19 mRNA疫苗第1剂和/或第2剂,主要结局为热性惊厥。
- 采用条件泊松回归估计发生率比(IRR)及95%置信区间(CI),并用荟萃分析合并各数据库结果。
主要发现
- 主要荟萃分析显示,接种mRNA-1273后0-1天热性惊厥发生率显著升高(IRR 2.52,95%CI 1.35-4.69),风险差(RD)/10万剂为3.22(95%CI -0.31至6.75)。
- 接种BNT162b2后IRR升高但无统计学意义(IRR 1.41,95%CI 0.48-4.11),RD/10万剂为-0.25(95%CI -2.75至2.24)。
临床怎么用
- 对2-5岁儿童接种mRNA-1273后0-1天应关注热性惊厥发生,但绝对风险增加较小。
- 接种BNT162b2后热性惊厥风险未达统计学显著升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2-5 years. METHODS: The primary analysis evaluated children who had a febrile seizure outcome in the 0-1 days following COVID-19 vaccination. A self-controlled case series analysis was performed in three commercial insurance databases to compare the risk of seizure in the risk interval (0-1 days) to a control interval (8-63 days). The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA vaccinations. The primary outcome was febrile seizure (0-1 day risk interval). A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-analyses were used to pool results across databases. RESULTS: The primary meta-analysis found a statistically significant increased incidence of febrile seizure, in the 0-1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95% CI -0.31 to 6.75)). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95% CI: 0.48 to 4.11, RD/100,000 doses = -0.25 (95% CI -2.75 to 2.24). CONCLUSIONS: Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1 days following the mRNA-1273 vaccination.
引用
- Anderson SA, Smith ER, Wan Z, et al. Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years. Vaccine. 2026. PMID: 41643233. doi:10.1016/j.vaccine.2026.128225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。